CalciMedica Inc. (NASDAQ:CALC – Get Free Report) was the recipient of a significant drop in short interest in the month of April. As of April 30th, there was short interest totaling 167,953 shares, a drop of 54.9% from the April 15th total of 372,157 shares. Currently, 1.8% of the company’s stock are short sold. Based on an average daily volume of 151,788 shares, the short-interest ratio is presently 1.1 days.
Wall Street Analysts Forecast Growth
CALC has been the subject of a number of recent research reports. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a report on Thursday, January 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CalciMedica in a report on Wednesday, January 21st. Wall Street Zen upgraded CalciMedica to a “sell” rating in a report on Saturday, January 17th. Finally, Oppenheimer decreased their target price on CalciMedica from $20.00 to $10.00 and set an “outperform” rating for the company in a report on Thursday, March 5th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.
Read Our Latest Stock Report on CalciMedica
CalciMedica Stock Performance
CalciMedica (NASDAQ:CALC – Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter. Research analysts forecast that CalciMedica will post -1.21 EPS for the current fiscal year.
Institutional Trading of CalciMedica
Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in shares of CalciMedica in the 4th quarter valued at about $127,000. Cetera Investment Advisers lifted its holdings in shares of CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares during the last quarter. PVG Asset Management Corp purchased a new stake in shares of CalciMedica in the 4th quarter valued at about $302,000. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in shares of CalciMedica in the 3rd quarter valued at about $165,000. Finally, Meritage Portfolio Management lifted its holdings in shares of CalciMedica by 33.8% in the 3rd quarter. Meritage Portfolio Management now owns 61,539 shares of the company’s stock valued at $189,000 after purchasing an additional 15,539 shares during the last quarter.
About CalciMedica
CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.
The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.
Featured Articles
- Five stocks we like better than CalciMedica
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
